◆ 会议时间：2022年12月7日至10日
◆ 会议地点：瑞士 日内瓦/Geneva, Switzerland

◆ 会议简介：

2022年ESMO免疫肿瘤学大会将于2022年12月7日至10日在瑞士日内瓦举行，会议由欧洲肿瘤内科学会（ESMO）组织。ESMO免疫肿瘤学大会是一个全球性会议，从免疫疗法的基础知识到最新的研究结果；从了解不同的治疗方案到毒性的管理和最新数据的解读，ESMO免疫肿瘤学大会将满足对癌症治疗这一热门领域感兴趣的肿瘤学利益相关者的不同需求。

欧洲肿瘤内科学会（ESMO）成立于1975年，是全球领先的肿瘤内科学专业组织。ESMO是肿瘤学教育和信息的参考学会，现在全球160多个国家和地区拥有超过25,000余名会员；ESMO致力于通过宣促进多学科的癌症护理，支持肿瘤学家的专业发展以及在全球倡导可持续的癌症护理，尽而为癌症患者提供最佳的护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com)

摘要征集：

Outcome notifications

Outcome notifications are expected to be made available to first authors by mid-October 2022.

Detailed instructions for the preparation of presentations and posters will be made available on the ESMO website by end October 2022 along with scheduling notices.

Abstract submission deadlines

*A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline (27 September 2022).

Final versions must be submitted by 2 November 2022, 21:00 CEST (Central European Time).

点此提交摘要>>>Submit Abstract>>>

ESMO I-O 2022 Abstract Regulations

Abstract submission categories

• Biomarker development 
• Cell therapy immune engineering  
• Clinical practice 
• Therapeutic development 
• Tumour biology and tumour microenvironment
• Miscellaneous

Late-breaking abstracts

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes. 

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 27 September 2022 will be considered for late-breaking status. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to ESMO Immuno-Oncology Congress 2022, and a pre-planned analysis must be scheduled between the regular submission deadline of 27 September 2022 and the late-breaking submission deadline of 2 November 2022.

Trial in Progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Immuno-Oncology Congress 2022. It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

• Background
• Trial design 

Notes:

• Recruitment must have already begun or have been completed by the abstract submission deadline of 27 September 2022.
• Abstracts including results or preliminary data will be rejected.
• Trial in Progress abstracts will not be considered for Proffered Paper (oral) presentation or Mini Oral.
• Encore TiP abstracts will be rejected.  Trial in Progress (TiP) abstracts will be reviewed by the ESMO Immuno-Oncology Congress 2022 Scientific Committee and considered on the merits of the scientific and clinical rationale of the trial.

Publications

All accepted abstracts, including Late-breaking, will be published online only in the ESMO Immuno-Oncology Congress 2022 Abstract Book, a supplement to the official ESMO journal, Immuno-Oncology and Technology (IOTECH).

Presentation of accepted abstracts

The ESMO Immuno-Oncology Congress 2022 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
• Poster – Display sessions for review, discussion and questions. Posters will be displayed for one day of the Congress and the presenting authors must be available for Q&A for one hour to represent their work.

Publication schedule for accepted abstracts 

• Abstracts accepted for presentation at ESMO Immuno-Oncology Congress 2022 as Proffered Paper, Mini Oral and Poster will be published online on the ESMO website at 00:05 CET on Thursday, 1 December 2022.
• All Late-breaking abstracts accepted for presentation at ESMO Immuno-Oncology Congress 2022 as Proffered Paper or Mini Oral (prefix LBA) will be published online via the ESMO website at 00:05 CEST on Tuesday, 6 December 2022.
• Details regarding the publication of abstracts selected for ESMO PR activities will be made available two weeks prior to the ESMO Immuno-Oncology Congress.

注册费：

The ESMO Immuno-Oncology Congress 2022 will take place on-site in Geneva, Switzerland and online in a virtual format.

During the registration process delegates will be asked to indicate on-site or online participation.  N.B. On-site participation also includes access to the online platform.

Registration fees and deadlines 

Individual registration will remain open for the duration of the meeting. The ESMO Congress Secretariat must receive one completed registration per participant and the corresponding payment in EUR by the given deadlines.

* Applicable to ESMO members from developing countries only.
At the time of application, developing countries are defined by ESMO according to the World Bank classification of low, lower-middle and upper-middle countries based on the Gross National Income (GNI) per capita. Download the PDF outlining which countries are eligible for the discounted registration fees.
**ESMO Members must be under 40 and in training to qualify for this fee.

In-person participation includes:

• Participation in scientific and educational live sessions with the possibility to interact with the expert panel table
• On-site networking opportunities with faculty and peers
• Entry to the Poster and e-Poster area
• Interaction with the industry partners in the trade exhibition
• Participation in the Industry Satellite Symposia
• Access to the Virtual Platform to view sessions missed on-demand
• Post-event resources
• Coffee breaks and lunches

Online participation includes:

• Access to the Virtual Platform, with live streaming of all sessions
• Possibility to interact through the chat live discussion
• Access to e-Posters
• Entry to the virtual exhibition
• Participation in the Industry Satellite Symposia
• Post-event resources

Please note that until 16 November 2022 an on-site registration can be changed to online and vice versa, at no additional charge.

◆ 参会对象：：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。